Cachexia is a syndrome characterized by an ongoing loss of skeletal muscle mass 21 associated with poor patient prognosis in non-small cell lung cancer (NSCLC). However, prognostic 22 cachexia biomarkers in NSCLC are unknown. Here, we analyzed computed tomography (CT) 23 images and tumor transcriptome data to identify potentially secreted cachexia biomarkers (PSCB) 24 in NSCLC patients with low-muscularity. We integrated radiomics features (pectoralis muscle, 25 sternum, and T10 vertebra) from CT of 89 NSCLC patients, which allowed us to identify an index 26 for screening muscularity. Next, a tumor transcriptomic-based secretome analysis from these 27 patients (discovery set) was evaluated to identify potential cachexia biomarkers in patients with 28 low-muscularity. The prognostic value of these biomarkers for predicting recurrence and survival 29 outcome was confirmed using expression data from eight lung cancer datasets (validation set).
151 length (OS); T10 body vertical length (T10-I); distance between T10 body and spinous process (T10-152 II); T10 body horizontal length (T10-III); distance between T10 pedicles (T10-IV); distance between 153 T10 transverse processes (T10-V); T10 body area (T10-VI); anteroposterior distance (APD). (b) Bar 154 graphs comparing the percentage of patients for clinical prognostic variables between high and low 155 muscularity groups. These groups were generated based on the ordination of patients according to 156 their PMA in descending order using a sex-specific categorical variable followed by segregation into 
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Protein-protein interaction (PPI) network of 75 up-regulated transcripts in patients with low 175 muscularity generated by STRING using a high confidence interaction score (0.700). 
185
The prognostic value related to the worse prognosis of IL8, SCG2, NCAM1, CNTN1, CADM1, 186 NPTX1, and APOD transcripts were evaluated in seven lung cancer transcriptome datasets 187 (validation set). Notably, these biomarkers were capable of distinguishing worse and better prognosis 188 (recurrence and survival) in seven NSCLC cohorts from the SurvExpress database ( Figure 4c ).
189
Interestingly, only IL8 was found with increased expression in the high-risk group in all NSCLC 190 validation set (Figure 4d and Supplementary Figure 3 ). 
218
were validated as over-expressed in patients with worse overall survival ( Supplementary Figure 4 ).
219
Importantly, IL6, IL8, IL1R2, CEMIP, FCGR3B, and KIF1A are predicted as a potentially secreted 220 protein in at least two secretome databases ( Supplementary Table 2 ). Collectively, these results 221 emphasize that IL8 is highly expressed in tumors from NSCLC patients with low muscularity and is 222 associated with poor prognosis in this cancer type. 
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Using a tumor transcriptome-based secretome analysis in NSCLC patients with low 251 muscularity, we aimed to identify potential cancer biomarkers of prognostic value and mediators of 252 cancer-associated muscle loss. This strategy revealed increased expression levels of cachexia-related 253 genes predicted to be secreted in NSCLC from patients with lower PMA. These genes were further 254 associated with shorter recurrence-free survival and decreased overall survival in different validation 255 sets of patients with NSCLC. Importantly, increased expression levels of IL8 was detected in the high-
256
risk group in all NSCLC validation sets, and IL-8 was sufficient to trigger atrophy in C2C12 257 myotubes.
258
Muscle depletion or low muscle mass in NSCLC patients identified by CT images has been 259 extensively associated with poor outcome [4, [9] [10] [11] [12] [13] 15, 16] . Previous studies using the same 
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Although a large range of changes in body composition has been associated with tumor-derived 275 factors, including many pro-inflammatory cytokines [17] [18] [19] 38] , only few NSCLC studies associated
276
CT-derived body composition with systemic inflammatory response [39, 40] . These studies showed 277 that lower muscularity was associated with systemic inflammatory response (IL-6, C-reactive protein,
278
and albumin blood levels, and neutrophil-to-lymphocyte ratio). However, the specific tumor-derived (CSF3, IL8, IL6, BMP6, SCG2, CCL8, BMP2 ) and extracellular space FLRT2, IL8, PLA2G3, IL6, ATP1B1, COL14A1, LPL, HBB, ADAMTS4) . These results suggest 284 that tumor of patients with low muscularity possibly secrete cachexia associated-factors.
285
The in-silico analysis confirmed that a set of over-expressed genes are translated into proteins coding for secreted proteins that may constitute potential mediators of muscle loss in NSCLC.
297
Based on the fact that circulating levels of tumor-derived factors were correlated with cachexia 298 development and predicted outcome in cancer [28, 30, [41] [42] [43] [44] [45] [46] [47] [48] , we also investigated the predictive 299 potential of seven transcripts (NCAM1, CNTN1, SCG2, CADM1, IL8, NPTX1, and APOD). All of them 300 were associated with shorter overall survival and recurrence-free survival for the predicted high-risk 301 groups in the NSCLC validation set. However, only IL8 was over-expressed in the high-risk group in 302 all cohorts of our NSCLC validation set. We further confirmed that high IL8 expression level in tumor 303 tissue is a strong predictive biomarker significantly associated with worse survival (validation cohort 304 of 1053 NSCLC patients). In agreement with our results, IL-8 expression in tumor tissues was recently 305 associated with cachectic status and outcome in pancreatic cancer; cachectic patients with high IL-8 306 expression in tumor tissues had shorter overall survival or disease-free survival [[30] ]. Importantly, 307 these authors also showed that IL-8 expression level in tumor specimen paired with serum sample 308 from the same patients was associated with tumor size.
309
We demonstrated that IL-8 directly induce myotube atrophy, reinforcing its potential as a new 310 mediator of cancer cachexia. Muscle wasting in cancer cachexia has been attributed to the 311 combinatorial action of mediators from host and tumor microenvironment [17] [18] [19] 38] . Also, tumor 312 expression and serum levels of IL-8 have been associated with muscle wasting in patients with 313 different tumor types [28, 30, [41] [42] [43] [44] [45] . The potential direct effect of IL-8 in inducing muscle cell atrophy 314 is still unknown. In this study, we provide evidence that IL-8 is a biomarker of worse prognosis that 315 has the potential to define the cachectic state in NSCLC patients
316
The main strength of the present investigation is the identification of potential tumor-derived 317 mediators of muscle wasting in patients with low muscularity, which have prognostic value in
318
NSCLC. However, our study is based on the reuse of transcriptomic and clinical data, which results
319
in limitations that can be pointed out. Firstly, the validation of the findings at protein levels in NSCLC 320 patients with low muscularity would be a strategy to define the cachexia blood biomarkers useful for 321 clinical routine. Secondly, our survival analyses were restricted to the validation set; the survival 322 information was not available in our discovery dataset. Finally, since the IL8 gene is not present in 
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We also compared the PMA with muscle normalizations based on different radiomics features,
355
as previously described [57] [58] [59] , to test different approaches for screening muscularity in NSCLC 356 patients. For this purpose, the pectoralis muscle area was also normalized by the following sternum 357 measurements: 1) manubrium length; 2) sternum body length; 3) total manubrium and sternum body 358 lengths; 4) distance between the beginning of manubrium and the end of sternum body measured in 359 90º (not considering the xiphoid process) (Supplementary figure 1a) . Different T10 vertebrae 360 measurements were also tested for muscle normalizations: 1) horizontal length of T10 body; 2) 361 vertical length of T10 body; 3) distance between T10 body and spinous process; 4) distance between 362 transverse processes; 5) distance between pedicles; and 6) T10 body area. We also analyzed the body 363 cross-section anteroposterior diameter (APD) at the tenth thoracic vertebra (T10) level to normalize 364 the muscle area ( Supplementary Figure 1b) . The bone images were selected in the cross-section where 365 the bones appeared at a higher extent and dimension. The measurements were performed at the tenth 366 thoracic vertebra (T10), which is a common region for all patients in this CT collection. Skeletal muscle 367 index (or muscularity) was defined as the PMA divided by each bone or body measure (mentioned 368 above) squared (cm 2 /cm 2 ). The measurements generated were z-score normalized and submitted to 369 a non-hierarchical k-means clustering analysis using Bioconductor Package Complex Heatmap (v 3.5)
370
in RStudio software (http://www.rstudio.org/). 
